Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecaprevir/pibrentasvir - AbbVie

Drug Profile

Glecaprevir/pibrentasvir - AbbVie

Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; HCV Next Gen; MAVIRET; MAVYRET; Pibrentasvir/glecaprevir; Pibrentasvir/glecaprevir-Abbvie

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 18 Oct 2019 AbbVie completes a phase III trial in Hepatitis C (Treatment-naive) in USA, Bulgaria, Canada, Czech republic, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Romania, Russia, Spain, Puerto Rico, Vietnam, Taiwan, United Kingdom (PO) (NCT03089944)
  • 26 Sep 2019 The US FDA approves glecaprevir/pibrentasvir to shorten once-daily treatment duration from 12 to 8 weeks in cirrhotic patients with Hepatitis C (Treatment-naive) with genotype 1, 2, 4, 5, or 6 infection
  • 06 Aug 2019 9272124- update only, info added in KDM and updated TT and AE data, intro updated, HE added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top